Epitope-based vaccines: an update on epitope identification, vaccine design and delivery

被引：243

作者：

Sette, A

Fikes, J

机构：

[1] La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA

[2] Epimmune, San Diego, CA 92121 USA

来源：

CURRENT OPINION IN IMMUNOLOGY | 2003年 / 15卷 / 04期

关键词：

D O I：

10.1016/S0952-7915(03)00083-9

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The basic premise of the epitope-based approach to vaccine development is that, in certain cases, the responses induced by the natural immunogen are not optimal, and can be improved upon by isolation or optimization of specific components of the response. For example, immunodominance is a key factor limiting the type and breadth of adaptive immunity. Recent advances in understanding the mechanisms of immunodominance thus represent an opportunity to further develop the epitope-based approach.

引用

收藏

页码：461 / 470

页数：10

相关论文

共 140 条

[61]

Lauemoller S L, 2000, Rev Immunogenet, V2, P477

[62] Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study [J].

Le Gal, FA ;

Prevost-Blondel, A ;

Lengagne, R ;

Bossus, M ;

Farace, F ;

Chaboissier, A ;

Gras-Masse, H ;

Engelhard, VH ;

Guillet, JG ;

Gahéry-Ségard, H .

INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (02) :221-227

[63] Cytotoxic T cell polyepitope vaccines delivered by ISCOMs [J].

Le, TTT ;

Drane, D ;

Malliaros, J ;

Cox, JC ;

Rothel, L ;

Pearse, M ;

Woodberry, T ;

Gardner, J ;

Suhrbier, A .

VACCINE, 2001, 19 (32) :4669-4675

[64] Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma [J].

Lee, P ;

Wang, F ;

Kuniyoshi, J ;

Rubio, V ;

Stuges, T ;

Groshen, S ;

Gee, C ;

Lau, R ;

Jeffery, G ;

Margolin, K ;

Marty, V ;

Weber, J .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3836-3847

[65] Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity [J].

Leifert, JA ;

Harkins, S ;

Whitton, JL .

GENE THERAPY, 2002, 9 (21) :1422-1428

[66] A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion [J].

Linard, B ;

Bézieau, S ;

Benlalam, H ;

Labarrière, N ;

Guilloux, Y ;

Diez, E ;

Jotereau, F .

JOURNAL OF IMMUNOLOGY, 2002, 168 (09) :4802-4808

[67] Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines [J].

Livingston, BD ;

Newman, M ;

Crimi, C ;

McKinney, D ;

Chesnut, R ;

Sette, A .

VACCINE, 2001, 19 (32) :4652-4660

[68]

Lu J, 2002, CANCER RES, V62, P5807

[69] TAP-Independent presentation of CTL epitopes by trojan antigens [J].

Lu, J ;

Wettstein, PJ ;

Higashimoto, Y ;

Appella, E ;

Celis, E .

JOURNAL OF IMMUNOLOGY, 2001, 166 (12) :7063-7071

[70] Human leucocyte antigen supertypes and immune susceptibility to HIV-1, implications for vaccine design [J].

MacDonald, KS ;

Matukas, L ;

Embree, JE ;

Fowke, K ;

Kimani, J ;

Nagelkerke, NJD ;

Oyugi, J ;

Kiama, P ;

Kaul, R ;

Luscher, MA ;

Rowland-Jones, S ;

Ndinya-Achola, J ;

Ngugi, E ;

Bwayo, JJ ;

Plummer, FA .

IMMUNOLOGY LETTERS, 2001, 79 (1-2) :151-157

← 2 3 4 5 6 7 8 9 10 11 →